MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales.
Agreement enables Helsinn to expand into oncology therapeutics with new Phase III-ready asset
MEI Pharma to host conference call today at 9:00 am Eastern time
Click the following link for the press release:
Linkedin